Does loxiglumide increase plasma CCK during fat infusion?
What the Evidence Shows
We analyzed one assertion on whether loxiglumide increases plasma CCK during fat infusion, and all available evidence supports this observation. When healthy young adults received loxiglumide through an IV while fat was slowly delivered into their small intestine, their blood levels of cholecystokinin — a hormone involved in digestion and appetite — rose instead of dropping as expected [1]. This suggests the body’s normal feedback system for regulating this hormone may respond in an unusual way when loxiglumide is present.
We don’t yet know why this happens. Loxiglumide is known to block certain receptors that typically reduce CCK release, so it’s possible that blocking those receptors interferes with the usual signal to lower CCK after fat enters the gut. But we only have one clear observation to work with, and no studies contradict this finding. The evidence we’ve reviewed so far leans toward the idea that loxiglumide can cause CCK levels to increase during fat infusion, but we can’t say how consistent this effect is across different people, doses, or conditions.
This result is interesting because it shows the body’s hormone control system can behave unpredictably when a blocker like loxiglumide is introduced. For now, we can only say that under the specific conditions tested — intravenous loxiglumide with duodenal fat infusion in healthy young adults — CCK levels went up. More research would be needed to see if this happens in other groups or with different methods of delivery.
If you’re curious about how drugs affect digestion, this shows that even small changes in hormone signaling can lead to unexpected outcomes.
Evidence from Studies
Update History
- Invalid DateNew topic created from assertion